4.5 Article

Lack of Killer Immunoglobulin-Like Receptor 2DS2 (KIR2DS2) and KIR2DL2 Is Associated with Poor Responses to Therapy of Recurrent Hepatitis C Virus in Liver Transplant Recipients

Journal

LIVER TRANSPLANTATION
Volume 15, Issue 11, Pages 1557-1563

Publisher

WILEY
DOI: 10.1002/lt.21878

Keywords

-

Ask authors/readers for more resources

Killer immunoglobulin-like receptors (KIRs) expressed on natural killer and natural killer T cells are involved in activation of these cells and can influence antiviral immunity in the liver. This study investigated the association between KIR genetic diversity and sustained virologic response (SVR) to Peginterferon and Ribavirin (Peg/RBV) therapy in liver transplant (LT) recipients with hepatitis C virus (HCV) recurrence. We tested KIR genotypes in 44 HCV-infected LT recipients treated with Peg/RBV for 48 weeks. Patients were categorized as having KIR genotypes A/A or B/x and analyzed for association with SVR. Fifteen of 44 (34%) patients had SVR. Only 2 of 18 (11%) who lacked KIR2DS2/KIR2DL2 achieved SVR compared to 13 of 26 (50%) who carried these two genes (odds ratio: 8.0, 95% confidence interval: 1.5-42.0, P = 0.008). The association between lack of KIR2DS2/KIR2DL2 and SVR remained significant after exclusion of 10 patients with non-genotype 1 HCV. No correlation was found with other activating or inhibitory KIR genes. Absence of KIR2DS2 and/or KIR2DL2 is associated with failure of Peg/RBV therapy in patients with recurrent HCV after LT. These findings support the role of natural killer and natural killer T cells in HCV clearance after LT and might be generalizable to treatment of HCV infection outside the setting of LT. Liver Transpl 15:1557-1563, 2009. (C) 2009 AASLD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

Induction Therapy With Antithymocyte Globulin and Delayed Calcineurin Inhibitor Initiation for Renal Protection in Liver Transplantation: A Multicenter Randomized Controlled Phase II-B Trial

Amit Nair, Laia Coromina Hernandez, Shimul Shah, Xaralambos Zervos, Michael Zimmerman, Kazunari Sasaki, Teresa Diago, Koji Hashimoto, Masato Fujiki, Federico Aucejo, Jessica Bollinger, Tiffany L. Kaiser, Charles M. Miller, Cristiano Quintini, John J. Fung, Bijan Eghtesad

Summary: In liver transplantation, delaying the initiation of calcineurin inhibitors (CNI) and using induction rabbit antithymocyte globulin (rATG) may help preserve early kidney function, especially when CNI initiation is delayed beyond 10 days or target tacrolimus levels are lower.

TRANSPLANTATION (2022)

Article Surgery

Combined heart-liver-kidney transplant: The university of Chicago medicine experience

Angelica Perez-Gutierrez, Umar Siddiqi, Gene Kim, Govind Rangrass, Aalok Kacha, Valluvan Jeevanandam, Yolanda Becker, Lisa Potter, John Fung, Talia B. Baker

Summary: This paper presents the best practices for successful execution of combined heart-liver-kidney transplantation, including patient selection, perioperative planning, and coordination among transplant teams. By careful selection and collaboration, this highly challenging operation can be successfully performed.

CLINICAL TRANSPLANTATION (2022)

Editorial Material Gastroenterology & Hepatology

The Sky Is Not Falling

John J. Fung

LIVER TRANSPLANTATION (2022)

Article Immunology

Nonhepatic Cancer in the Pediatric Liver Transplant Population: Guidelines From the ILTS-SETH Consensus Conference

Mohamed Rela, Jesus Quintero, Mureo Kasahara, Paolo Muiesan, Francisco Hernandez-Oliveros, Rajesh Rajalingam, Sadhana Shankar, Blayne Amir Sayed, Diego di Sabato, Ashwin Rammohan, John Fung, Itxarone Bilbao

Summary: The incidence and distribution of cancers in children are different from adults. Nonhepatic cancers should be considered in pediatric liver transplantation. With longer post-transplant survival and increased risk of new cancers, guidelines and best practices are needed for nonhepatic cancers in pediatric liver transplantation.

TRANSPLANTATION (2022)

Editorial Material Gastroenterology & Hepatology

Perspective: Advances in liver transplantation for hepatocellular carcinoma-A prototype for transplant oncology

John Fung, Diego DiSabato, Chih-Yi Liao, Osmanuddin Ahmed, Anjana Pillai

HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2023)

Article Oncology

Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma

Aditya Juloori, Rohan R. Katipally, Jeffrey M. Lemons, Anurag K. Singh, Renuka Iyer, Jared R. Robbins, Ben George, William A. Hall, Sean P. Pitroda, Fauzia Arif, John Fung, Anjana Pillai, Chih-Yi Liao, Manish Sharma, Stanley L. Liauw

Summary: This study investigated the safety and efficacy of stereotactic body radiation therapy (SBRT) with immunotherapy in patients with hepatocellular carcinoma (HCC). The results showed that the combination of SBRT with nivolumab plus ipilimumab had better survival and efficacy compared to immunotherapy alone in HCC patients, suggesting the need for further investigation.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma

Osman Ahmed, Qian Yu, Mikin Patel, Gloria Hwang, Anjana Pillai, Chih-yi Liao, John Fung, Talia Baker

Summary: A combination therapy of yttrium-90 transarterial radioembolization (TARE) and systemic gemcitabine, cisplatin, and capecitabine is safe and effective for the first-line treatment of locally advanced intrahepatic cholangiocarcinoma (iCCA), resulting in high rates of downstaging and favorable overall survival.

JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2023)

Article Surgery

Deceased donor kidneys from higher distressed communities are significantly less likely to be utilized for transplantation

Jesse D. Schold, Anne M. Huml, S. Ali Husain, Emilio D. Poggio, R. Blake Buchalter, Rocio Lopez, Bruce Kaplan, Sumit Mohan

Summary: In the United States, over 20% of procured kidneys for transplantation are not utilized. This study examined the factors associated with nonutilization and found that deceased donors from higher distressed communities were more likely to have their kidneys not utilized. The study also found regional variations in kidney nonutilization rates and minimal impact on recipient outcomes.

AMERICAN JOURNAL OF TRANSPLANTATION (2023)

Review Medicine, General & Internal

Comparing High- and Low-Model for End-Stage Liver Disease Living-Donor Liver Transplantation to Determine Clinical Efficacy: A Systematic Review and Meta-Analysis (CHALICE Study)

Kumar Jayant, Thomas G. Cotter, Isabella Reccia, Francesco Virdis, Mauro Podda, Nikolaos Machairas, Ramesh P. Arasaradnam, Diego Di Sabato, John C. LaMattina, Rolf N. Barth, Piotr Witkowski, John J. Fung

Summary: This study compared the outcomes of high-MELD and low-MELD living-donor liver transplant recipients and found no significant differences in patient survival, graft survival, and most complications between the two groups. However, the high-MELD group had a higher risk of pulmonary infection, abdominal fluid collection, and prolonged ICU stay.

JOURNAL OF CLINICAL MEDICINE (2023)

Meeting Abstract Immunology

Safety and Effectiveness of COVID-19 Vaccination in the Islet Transplant Recipients

Mateusz Ogledzinski, Piotr J. Bachul, Braden Juengel, Yaser Al-Salmay, Jayant Kumar, Angelica Perez-Gutierrez, Lindsay Basto, Laurencia Perea, Ling-Jia Wang, Martin Tibudan, Rolf Barth, John Fung, Piotr Witkowski

TRANSPLANTATION (2022)

Meeting Abstract Immunology

A Positive B2 Microglobulin Trend Immediately After Transplant Identify Worse Outcomes in Patients With Delayed Graft Function

Angelica Perez-Gutierrez, Braden Juengel, Piotr J. Bachul, Yaser AlSalmay, Piotr Witkowski, John Fung, Yolanda T. Becker, Rolf N. Barth

TRANSPLANTATION (2022)

Meeting Abstract Gastroenterology & Hepatology

ANALYSIS OF SURVIVAL BENEFITS OF LIVING AND DECEASED DONOR LIVER TRANSPLANTATION FOR PATIENTS WITH LOW MODEL OF END STAGE LIVER DISEASE SCORE

Tiffany C. L. Wong, Shirley T. L. Chiu, James Fung, Chung Mau Lo

HEPATOLOGY (2022)

Meeting Abstract Surgery

The β2 Microglobulin Trend Is A Marker Of Delayed Graft Function After Kidney Transplantation

Angelica Perez-Gutierrez, Piotr Bachul, Yaser AlSalmay, Piotr Witkowski, Rolf Barth, Diego DiSabato, John Fung, Yolanda Becker

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Meeting Abstract Surgery

Modified approach for improved islet allotransplantation into prevascularized Sernova Cell Pouch™device - preliminary results of the phase I and II clinical study at University of Chicago

Piotr Bachul, Angelica Perez-Guetierrez, Yaser Al-Salmay, Braden Juengel, Kumar Jayant, Lindsay Basto, Ling-Jia Wang, Laurencia Perea, Martin Tibudan, Celeste Thomas, Rolf Barth, John Fung, Piotr Witkowski

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Meeting Abstract Surgery

Histidine-tryptophan-ketoglutarate Solution Is Superior To University Of Wisconsin Solution In Donation After Circulatory Death Liver Transplantation

Angelica Perez-Gutierrez, Thomas Cotter, Mathew Odenwald, Kumar Jayant, Diego DiSabato, Michael Charlton, John Fung

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

No Data Available